Neurogene Inc. Number of Reportable Segments
Neurogene Inc. (NGNE) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-11
- Neurogene Inc. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- Neurogene Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment, a 0.00% change year-over-year.
- Neurogene Inc. number of reportable segments for the quarter ending 2024-03-31 was 1.00 segment.
- Neurogene Inc. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- Neurogene Inc. number of reportable segments for fiscal 2024 was 1.00 segment, a 0.00% change from fiscal 2023.
- Neurogene Inc. number of reportable segments for fiscal 2023 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-03-24 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-24 | |||
| 2024-09-30 | 1.00 segment 10-Q · filed 2024-11-18 | |||
| 2024-06-30 | 1.00 segment 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | 1.00 segment 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | 1.00 segment 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |